- Home
- OFS vs TARA Comparison
OFS vs TARA Comparison
Compare OFS & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- TARA
- Stock Information
- Founded
- OFS 2001
- TARA N/A
- Country
- OFS United States
- TARA United States
- Employees
- OFS N/A
- TARA N/A
- Industry
- OFS Finance/Investors Services
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OFS Finance
- TARA Health Care
- Exchange
- OFS Nasdaq
- TARA Nasdaq
- Market Cap
- OFS 110.3M
- TARA 130.8M
- IPO Year
- OFS 2012
- TARA N/A
- Fundamental
- Price
- OFS $8.75
- TARA $3.19
- Analyst Decision
- OFS
- TARA Strong Buy
- Analyst Count
- OFS 0
- TARA 6
- Target Price
- OFS N/A
- TARA $20.60
- AVG Volume (30 Days)
- OFS 38.5K
- TARA 523.0K
- Earning Date
- OFS 05-01-2025
- TARA 05-08-2025
- Dividend Yield
- OFS 15.40%
- TARA N/A
- EPS Growth
- OFS N/A
- TARA N/A
- EPS
- OFS 2.25
- TARA N/A
- Revenue
- OFS $44,026,000.00
- TARA N/A
- Revenue This Year
- OFS N/A
- TARA N/A
- Revenue Next Year
- OFS N/A
- TARA N/A
- P/E Ratio
- OFS $3.92
- TARA N/A
- Revenue Growth
- OFS N/A
- TARA N/A
- 52 Week Low
- OFS $7.75
- TARA $1.60
- 52 Week High
- OFS $10.04
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- OFS 52.84
- TARA 37.68
- Support Level
- OFS $8.53
- TARA $3.00
- Resistance Level
- OFS $9.00
- TARA $3.51
- Average True Range (ATR)
- OFS 0.34
- TARA 0.20
- MACD
- OFS 0.02
- TARA -0.02
- Stochastic Oscillator
- OFS 38.46
- TARA 27.14
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).